Posted: 4 August 2025
Australian life sciences venture capital firm Brandon Capital confirmed the final close of its sixth fund- Brandon BioCatalyst Fund 6, exceeding $430 million AUD in commitments. This marked one of the largest life sciences venture raises in the Asia-Pacific region, aimed at supporting early and growth-stage biotechnology companies across Australia and New Zealand.
“We’re excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations through our unwavering scientific rigour and disciplined capital allocation, in pursuit of exceeding our investors’ expectations.”,” said Dr Chris Nave, Founder and Managing Partner at Brandon Capital.
This final close of Brandon BioCatalyst Fund Six (BB6) will see Brandon Capital continue to invest in emerging biomedical technologies with strong commercial potential, translating these exciting discoveries into high-growth firms that positively impact human health.
To date, Brandon Capital has raised over A$1 billion across previous funds with notable Fund Six investments to date including AdvanCell (radiopharma), PolyActiva (glaucoma implant), Myricx Bio (ADC) and CatalYm (oncology).
For more information click here.
